Replies to post #124482 on Biotech Values

[ghmm]

DNDN:

Here is an article which (among other things) agrees with your point about DNDN should have charged even more for Provenge.

http://www.forbes.com/sites/matthewherper/2011/09/08/what-if-weve-all-been-wrong-about-provenge/